

CITATION REPORT

List of articles citing

Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects

DOI: 10.1007/s00228-020-03023-7

European Journal of Clinical Pharmacology, 2021, 77, 527-537.

Source: <https://exaly.com/paper-pdf/78008921/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
28	Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 337-351	6.2	8
27	A novel approach for the treatment of hypertension with the soluble guanylate cyclase stimulating drug. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 635-640	4.1	0
26	Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 1407-1421	6.2	5
25	Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1847-1855	4.855	4
24	The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. <i>Heart Failure Reviews</i> , 2021 , 1	5	3
23	Vericiguat: A Novel Oral Soluble Guanylate Cyclase Stimulator for the Treatment of Heart Failure. <i>Annals of Pharmacotherapy</i> , 2021 , 10600280211041384	2.9	4
22	Soluble GC stimulators and activators: Past, present and future. <i>British Journal of Pharmacology</i> , 2021 ,	8.6	6
21	Nitric oxide soluble guanylate cyclase cyclic guanosine monophosphate signaling pathway in the pathogenesis of heart failure and search for novel therapeutic targets. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2021 , 20, 3035	0.9	
20	Vericiguat. <i>Cardiology in Review</i> , 2022 , Publish Ahead of Print,	3.2	1
19	Vericiguat en insuficiencia cardíaca: de la evidencia científica a la práctica clínica. <i>Revista Clínica Española</i> , 2022 ,	0.7	2
18	Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study.. <i>Clinical and Translational Science</i> , 2022 ,	4.9	2
17	Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations.. <i>Therapeutics and Clinical Risk Management</i> , 2022 , 18, 315-322	2.9	2
16	Vericiguat: The First Soluble Guanylate Cyclase Stimulator for Reduction of Cardiovascular Death and Heart Failure Hospitalization in Patients With Heart Failure Reduced Ejection Fraction.. <i>Journal of Pharmacy Practice</i> , 2022 , 8971900221087096	1.3	3
15	Discovery and Development of the Soluble Guanylate Cyclase Stimulator Vericiguat for the Treatment of Chronic Heart Failure. 2022 , 27-50		
14	Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFREF).. <i>Biomedicine and Pharmacotherapy</i> , 2022 , 149, 112894	7.5	4
13	Vericiguat: resultados del estudio VICTORIA. <i>Revista Española De Cardiología Suplementos</i> , 2022 , 22, 15-222		
12	Vericiguat in heart failure: From scientific evidence to clinical practice.. <i>Revista Clínica Española</i> , 2022 ,	0.5	0

11	Should vericiguat be initiated in geriatric inpatients with heart failure with reduced ejection fraction and a worsening heart failure event prior to discharge?. <i>European Journal of Hospital Pharmacy</i> , 2022 ,	1.6	
10	Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction. <i>American Journal of Cardiovascular Drugs</i> ,	4	2
9	Vericiguat: pharmacological profile. <i>Klinicka Farmakologie A Farmacie</i> , 2022 , 36, 77-80	0.1	
8	Population Pharmacokinetics of Vericiguat in Patients with Heart Failure with Reduced Ejection Fraction: An Integrated Analysis. <i>Clinical Pharmacology and Therapeutics</i> ,	6.1	1
7	Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives. 2022 , 14, 1964		0
6	Vericiguat in Heart Failure: Characteristics, Scientific Evidence and Potential Clinical Applications. 2022 , 10, 2471		3
5	Vericiguat: A New Hope for Heart Failure Patients. 2022 , 2022, 1-6		1
4	Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes.		0
3	Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults. 2023 , 62, 321-333		0
2	Vericiguat for the treatment of heart failure with reduced ejection fraction. 2023 , 21, 245-257		0
1	Identifying the patient with heart failure to be treated with vericiguat. 1-9		0